NZ582648A - Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof - Google Patents

Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Info

Publication number
NZ582648A
NZ582648A NZ582648A NZ58264807A NZ582648A NZ 582648 A NZ582648 A NZ 582648A NZ 582648 A NZ582648 A NZ 582648A NZ 58264807 A NZ58264807 A NZ 58264807A NZ 582648 A NZ582648 A NZ 582648A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
lercanidipine
composition according
calcium channel
silicon dioxide
Prior art date
Application number
NZ582648A
Other languages
English (en)
Inventor
Evangelos Karavas
Efthimios Koutris
Ioanna Koutri
Eleni Stathaki
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39223083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ582648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Priority to NZ582648A priority Critical patent/NZ582648A/en
Publication of NZ582648A publication Critical patent/NZ582648A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
NZ582648A 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof NZ582648A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ582648A NZ582648A (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ582648A NZ582648A (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
PCT/EP2007/006517 WO2009012791A1 (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Publications (1)

Publication Number Publication Date
NZ582648A true NZ582648A (en) 2012-06-29

Family

ID=39223083

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ582648A NZ582648A (en) 2007-07-23 2007-07-23 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
NZ582690A NZ582690A (en) 2007-07-23 2008-07-23 A composition comprising lercanidipine and an amount of a colloidal silicon dioxide from 5% to 25% by weight to enhance bioavailabilty and/or solubility

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ582690A NZ582690A (en) 2007-07-23 2008-07-23 A composition comprising lercanidipine and an amount of a colloidal silicon dioxide from 5% to 25% by weight to enhance bioavailabilty and/or solubility

Country Status (20)

Country Link
EP (2) EP2180883B1 (enExample)
JP (2) JP5769963B2 (enExample)
KR (2) KR101632079B1 (enExample)
CN (3) CN101784260A (enExample)
AU (2) AU2007356942B2 (enExample)
BR (2) BRPI0721883A2 (enExample)
CA (2) CA2691752C (enExample)
CO (1) CO6290639A2 (enExample)
CR (1) CR11285A (enExample)
EA (2) EA021645B1 (enExample)
EC (1) ECSP109984A (enExample)
ES (2) ES2622495T3 (enExample)
MA (1) MA31684B1 (enExample)
MX (2) MX2010000856A (enExample)
MY (1) MY153857A (enExample)
NZ (2) NZ582648A (enExample)
TN (2) TN2010000011A1 (enExample)
UA (2) UA97161C2 (enExample)
WO (2) WO2009012791A1 (enExample)
ZA (2) ZA201000586B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
KR101632079B1 (ko) * 2007-07-23 2016-06-20 파마덴 에스.에이. 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
CN104069500A (zh) * 2014-06-20 2014-10-01 湖南天地恒一制药有限公司 一种包含乐卡地平的药物组合物
CN105168165B (zh) * 2015-08-28 2018-06-26 江苏福邦药业有限公司 一种盐酸乐卡地平片及其制备方法
WO2018004379A1 (ru) * 2016-07-01 2018-01-04 Общество С Ограниченной Ответственностью "Гиостин" Средство в виде капсулы для лечения заболеваний суставов
WO2019165420A1 (en) 2018-02-26 2019-08-29 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
JP2023107429A (ja) * 2022-01-24 2023-08-03 東芝テック株式会社 読取装置
CN114533686B (zh) * 2022-02-15 2023-10-20 湖南普道医药技术有限公司 一种二氢吡啶类药物的口服固体制剂及其制备方法
KR20240040407A (ko) * 2022-09-21 2024-03-28 주식회사 종근당 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
BR9903490A (pt) * 1998-12-15 2000-09-26 Oscar Gold Processo para a preparação de composições farmacêuticas de liberação programada contendo nimodipine, que permitem a liberação gradual e a manuntenção da ação terapeutica
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
EP1694305B1 (en) * 2003-12-01 2019-10-16 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
UA89177C2 (ru) * 2003-12-01 2010-01-11 Рекордати Айрленд Лимитед Фармацевтическая композиция с контролируемым высвобождением, которая содержит лерканидипин
EP2063872B2 (en) * 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008068777A2 (en) * 2006-12-06 2008-06-12 Torrent Pharmaceuticals Limited Stable lercanidipine formulation
KR101632079B1 (ko) * 2007-07-23 2016-06-20 파마덴 에스.에이. 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법

Also Published As

Publication number Publication date
EP2170295A1 (en) 2010-04-07
ZA201000586B (en) 2011-03-30
NZ582690A (en) 2011-12-22
EP2180883B1 (en) 2017-01-11
BRPI0721883A2 (pt) 2014-02-18
CN103976968A (zh) 2014-08-13
AU2008280106A1 (en) 2009-01-29
JP5769963B2 (ja) 2015-08-26
CA2691752C (en) 2016-01-26
CR11285A (es) 2010-04-27
KR20100047848A (ko) 2010-05-10
CA2691752A1 (en) 2009-01-29
ES2537063T3 (es) 2015-06-02
MX2010000856A (es) 2010-04-30
ZA201001176B (en) 2010-11-24
UA97161C2 (ru) 2012-01-10
MA31684B1 (fr) 2010-09-01
ECSP109984A (es) 2010-04-30
AU2008280106B2 (en) 2014-03-20
WO2009012791A1 (en) 2009-01-29
TN2010000022A1 (en) 2011-09-26
AU2008280106A2 (en) 2010-02-25
TN2010000011A1 (en) 2011-09-26
EP2170295B1 (en) 2015-04-22
CN101784260A (zh) 2010-07-21
CO6290639A2 (es) 2011-06-20
AU2007356942A1 (en) 2009-01-29
EA201070160A1 (ru) 2010-06-30
CN101801347A (zh) 2010-08-11
KR20100045456A (ko) 2010-05-03
MY153857A (en) 2015-03-31
CA2693233A1 (en) 2009-01-29
EP2180883A1 (en) 2010-05-05
EA019614B1 (ru) 2014-05-30
EA021645B1 (ru) 2015-08-31
KR101512404B1 (ko) 2015-04-21
WO2009013306A1 (en) 2009-01-29
EA201000220A1 (ru) 2010-08-30
KR101632079B1 (ko) 2016-06-20
ES2622495T3 (es) 2017-07-06
AU2007356942B2 (en) 2011-12-15
BRPI0814666A2 (pt) 2017-05-09
JP2010534211A (ja) 2010-11-04
JP2010534220A (ja) 2010-11-04
UA99136C2 (ru) 2012-07-25
MX2010000801A (es) 2010-07-05
AU2008280106B9 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
AU2007356942B2 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
US12138255B2 (en) Pharmaceutical compositions of cabozantinib
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
CA2696977C (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2197424A2 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
US20110257159A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
EP2303233B1 (en) Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
TW202045148A (zh) 包含乙醯胺基酚及異布洛芬之醫藥組合物
EP4262759A1 (en) Immediate release solid dosage form comprising teriflunomide and method of preparation thereof
HK1199221A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
HK1141726A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 JUL 2014 BY CPA GLOBAL

Effective date: 20130117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 JUL 2017 BY CPA GLOBAL

Effective date: 20140710

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2018 BY DENNEMEYER + CO

Effective date: 20170622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2019 BY DENNEMEYER + CO.

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2020 BY DENNEMEYER CO.

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2022 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20210713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2023 BY DENNEMEYER + CO.

Effective date: 20220711

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230710

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2025 BY DENNEMEYER ET CO

Effective date: 20240715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250714